Sign In
Buy XERS
$5.89
-0.110 (-1.83%)
At Close: Jun 03, 2026
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
12:50pm, Friday, 25'th Oct 2024
Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative inj
Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +
02:00pm, Friday, 11'th Oct 2024
The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 4th - 10th, aiming to inspire discussion and provide investment ideas. WW International's pivot to GLP-1 medications raises co
Xeris Biopharma: Time For A Reassessment
11:33am, Wednesday, 09'th Oct 2024
Xeris Biopharma is trading above my Buy Threshold of $2.76 and is nearing a potential breakout above the $3.25 resistance level. The company shows strong revenue growth, driven by products like Gvoke
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 04'th Oct 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ
3 Penny Stocks to Buy With $500
10:20am, Friday, 30'th Aug 2024
Are you interested in investing in penny stocks?
Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript
11:56am, Thursday, 08'th Aug 2024
Start Time: 08:30 January 1, 0000 9:03 AM ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants John Shannon - CEO Steven
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
09:25am, Thursday, 08'th Aug 2024
Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago.
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know
11:05am, Thursday, 01'st Aug 2024
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
10:56am, Wednesday, 24'th Jul 2024
From a technical perspective, Xeris Biopharma Holdings, Inc. (XERS) is looking like an interesting pick, as it just reached a key level of support. XERS's 50-day simple moving average crossed above it
Xeris Biopharma unveils CEO succession plan, John Shannon to lead company
09:55am, Monday, 08'th Jul 2024
Xeris Biopharma Holdings (NASDAQ:XERS) announced a CEO succession plan with John Shannon taking over from Paul Edick on August 1, 2024. Edick, the current CEO and chairman, will retire from his roles
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01:05pm, Wednesday, 03'rd Jul 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024
07:00am, Monday, 03'rd Jun 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
Xeris to Participate in the Jefferies Global Healthcare Conference
07:00am, Thursday, 30'th May 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
Xeris Biopharma sees 1Q revenue jump on strength of product sales
10:14am, Thursday, 09'th May 2024
Xeris Biopharma Holdings (NASDAQ:XERS) revealed a robust growth trajectory in its first quarter, with total product revenue surging 25% compared to the previous year's quarter. Paul Edick, CEO of Xeri
